New short-course malaria cure could save thousands
NCT ID NCT05879224
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new way to cure vivax malaria, a type of malaria that can come back. Researchers gave a high daily dose of the drug primaquine for a short time, but only after a quick test to check for a genetic condition (G6PD deficiency) that could cause serious side effects. About 3000 people with vivax malaria in Indonesia took part. The goal was to see if this approach is safe and practical in real-world clinics.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for G6PD DEFICIENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Puskesmas Bhintuka
Mimika, Special Region of Papua, Indonesia
-
Puskesmas Hanura
Hanura, Lampung, Indonesia
-
Puskesmas Pasar Sentral
Mimika, Special Region of Papua, Indonesia
-
Puskesmas Tanjung Leidong
Labuhanbatu, North Sumatra, Indonesia
-
Puskesmas Timika
Mimika, Special Region of Papua, Indonesia
-
Puskesmas Wania
Mimika, Special Region of Papua, Indonesia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Newborn screening study aims to catch rare diseases at birth
- Can a short drug course end malaria relapses for good?
- Malaria drug combo under scrutiny: could tafenoquine interact?
- New hope for malaria patients with G6PD deficiency?
- 3-Day malaria cure could transform treatment
- New Short-Course malaria treatment could prevent relapses